Sevelamer carbonate (Renvela®)

DRUG4 trials

Sponsors

Genzyme, a Sanofi Company, Alebund Pharmaceuticals

Conditions

Chronic Kidney DiseaseChronic Kidney Disease(CKD)Chronic Kidney Disease, Receiving DialysisChronic Renal InsufficiencyDialysisESRD (End Stage Renal Disease)End-Stage Renal DiseaseHyperphosphataemia

Phase 3

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

CompletedNCT00268957

Genzyme, a Sanofi CompanyChronic Renal Insufficiency, End-Stage Renal Disease, Kidney Diseases

Start: 2006-01-31End: 2007-05-31Updated: 2014-03-19

An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis

CompletedNCT00681941

Genzyme, a Sanofi CompanyChronic Kidney Disease, Hyperphosphatemia

Start: 2006-01-31End: 2007-03-31Updated: 2015-03-20

AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

CompletedNCT07030595

Alebund PharmaceuticalsChronic Kidney Disease(CKD), Chronic Kidney Disease, Receiving Dialysis, Dialysis +3

Start: 2023-06-12End: 2025-05-30Updated: 2025-11-17

Unknown Phase

Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia

CompletedNCT01857024

Genzyme, a Sanofi CompanyChronic Kidney Disease, Hyperphosphataemia

Start: 2010-09-30End: 2012-10-31Updated: 2015-03-23